Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Maja D. Andersen, Peter Kamper, Alexander d’Amore, Michael Clausen, Hans Bentzen & Francesco d'Amore. (2019) The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor. Leukemia & Lymphoma 60:4, pages 927-933.
Read now
Read now
Haowei (Linda) Sun, Eshetu G. Atenafu, Richard Tsang, Vishal Kukreti, Theodore K. Marras, Michael Crump & John Kuruvilla. (2017) Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma. Leukemia & Lymphoma 58:11, pages 2607-2614.
Read now
Read now
M. C. Cheung, A. Prica, J. Graczyk, R. Buckstein & K. K. W. Chan. (2016) Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis. Leukemia & Lymphoma 57:8, pages 1865-1875.
Read now
Read now
Joanna Graczyk, Matthew C. Cheung, Rena Buckstein & Kelvin Chan. (2014) Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis. Leukemia & Lymphoma 55:1, pages 56-62.
Read now
Read now
Articles from other publishers (14)
Natalia Sh Lebedeva, Elena S. Yurina, Sabir S. Guseinov & Yury A. Gubarev. (2023) Influence of the position of the N-methyl group in tetra-(N-methylpyridyl)porphyrin on the features of its interaction with oligonucleotides. Spectral and thermochemical study. Dyes and Pigments 220, pages 111723.
Crossref
Crossref
Seyed Mahdi Seyedzadeh Sani, Mehrdad Sahranavard, Mahdi Jannati Yazdanabad, Mohsen Seddigh Shamsi, Sepideh Elyasi, Amir Hooshang Mohammadpour, Thozhukat Sathyapalan, Omid Arasteh, Vahid Ghavami & Amirhossein Sahebkar. (2022) The effect of concomitant use of Colony-Stimulating factors on bleomycin pulmonary toxicity – A systematic review and meta-analysis. International Immunopharmacology 112, pages 109227.
Crossref
Crossref
Alparslan Merdin, Merih Kızıl Çakar, Mehmet Sinan Dal, Duygu Mert, Jale Yıldız, Semih Başçı, Mehmet Bakırtaş, Tahir Darçın, Derya Şahin, Bahar Uncu Ulu, Tuğçe Nur Yiğenoğlu, Hikmetullah Batgi, Ayşegül Tetik, Dicle İskender & Fevzi Altuntaş. (2019) Evaluation of neutropenia-related outcomes in Hodgkin's lymphoma patients with moderate or severe neutropenia who received ABVD chemotherapy without using granulocyte-colony stimulating factor. Journal of Oncology Pharmacy Practice 26:4, pages 929-932.
Crossref
Crossref
Jessica Liliana Vargas Neri, Osvaldo Daniel Castelán Martínez, Gilberto Castañeda Hernández, Felipe Rodríguez Islas, Miguel Ángel Palomo Colli, Rodolfo Rivas Ruíz, Enrique López Aguilar, Yadira Betanzos Cabrera, Mara Medeiros Domingo & Patricia Clark. (2020) Adverse Drug Reactions Associated with Anthracyclinebased Chemotherapy in Mexican Cancer Pediatric Patients: Cohort Study. Latin american journal of clinical sciences and medical technology 2:2, pages 9-17.
Crossref
Crossref
Gaurav Goyal, Sri Harsha Tella, Shealeigh Funni, Anuhya Kommalapati, Jonathan W. Inselman, Nilay D. Shah, Ronald S. Go & Stephen M. Ansell. (2019) Association between facility volume and mortality of patients with classic Hodgkin lymphoma. Cancer 126:4, pages 757-764.
Crossref
Crossref
Pamela B. Allen & Jane N. Winter. (2019) Controversies in the Approach to Initial Therapy of Hodgkin Lymphoma. Current Oncology Reports 21:5.
Crossref
Crossref
Edmond M. Kwan, Sophie Beck, Eitan Amir, Michael A. Jewett, Jeremy F. Sturgeon, Lynn Anson-Cartwright, Peter W. Chung, Padraig R. Warde, Malcolm J. Moore, Philippe L. Bedard & Ben Tran. (2018) Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors. Clinical Genitourinary Cancer 16:1, pages e193-e199.
Crossref
Crossref
Yassine Lalami & Jean Klastersky. (2017) Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data. Critical Reviews in Oncology/Hematology 120, pages 163-179.
Crossref
Crossref
James A. Chiarotto & George Dranitsaris. (2015) FOLFOX chemotherapy can safely be given to neutropenic patients with early-stage colorectal cancer for higher dose intensity and fewer visits. Supportive Care in Cancer 24:6, pages 2533-2539.
Crossref
Crossref
Peter Johnson & Hayley McKenzie. (2015) How I treat advanced classical Hodgkin lymphoma. Blood 125:11, pages 1717-1723.
Crossref
Crossref
James A. Chiarotto & George Dranitsaris. (2013) Full-dose chemotherapy in early stage breast cancer regardless of absolute neutrophil count and without G-CSF does not increase chemotherapy-induced febrile neutropenia. Supportive Care in Cancer 21:10, pages 2727-2731.
Crossref
Crossref
Boris BöllHelen GörgenMichael FuchsAnnette PluetschowHans Theodor EichMario J. BargetziEckhart WeidmannChristian JunghanßRichard GreilAlexander ScherpeOliver SchmalzDennis A. EichenauerBastian von TresckowAchim RotheVolker DiehlAndreas EngertPeter Borchmann. (2013) ABVD in Older Patients With Early-Stage Hodgkin Lymphoma Treated Within the German Hodgkin Study Group HD10 and HD11 Trials. Journal of Clinical Oncology 31:12, pages 1522-1529.
Crossref
Crossref
Arnab Mukherjee & Wilbee D. Sasikala. 2013. Dynamics of Proteins and Nucleic Acids. Dynamics of Proteins and Nucleic Acids
1
62
.
Prahlad Ho, Peter Sherman & Andrew Grigg. (2012) Intermittent granulocyte colony‐stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia. European Journal of Haematology 88:5, pages 416-421.
Crossref
Crossref